Loading organizations...
§ Private Profile · Irvine, CA, USA
Clinical-stage biotechnology company developing transformative medicines for severe, underserved diseases, focused on CRPS-1.
Ambros Therapeutics is an Irvine, California-based clinical-stage biotechnology company developing transformative medicines for severe and underserved rare diseases. The enterprise is currently advancing neridronate, a non-opioid therapy licensed directly from Abiogen Pharma, targeting Complex Regional Pain Syndrome Type 1. This primary therapeutic asset is progressing through a Phase 3 registrational program scheduled to begin in the first quarter of 2026, having already received Breakthrough Therapy, Fast-Track, and Orphan Drug designations from the Food and Drug Administration. Operating under the leadership of Chief Executive Officer Jay Hagan, the pre-revenue venture relies on institutional capital to fund its clinical trials and regulatory pathways. To support these commercialization efforts, the firm secured $125 million in an oversubscribed Series A financing round backed by RA Capital Management and Enavate Sciences. Ambros Therapeutics was founded in 2025 by Vivek Ramaswamy and Keith Katkin.
Ambros Therapeutics has raised $125.0M across 1 funding round.
Ambros Therapeutics has raised $125.0M in total across 1 funding round.
Ambros Therapeutics has raised $125.0M in total across 1 funding round.
Ambros Therapeutics's investors include Trit Garg, Matthew Hammond, Massimo Di Martino, Adage Capital Management, Arkin Bio Ventures, Balyasny Asset Management, Janus Henderson Investors, Transhuman Capital.
Ambros Therapeutics has raised $125.0M across 1 funding round. Most recently, it raised $125.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $125M Series A | Trit Garg, Matthew Hammond | Massimo DI Martino, Adage Capital Management, Arkin BIO Ventures, Balyasny Asset Management, Janus Henderson Investors, Transhuman Capital | Announced |